Metabolic dysfunction-associated steatotic liver disease has similar outcomes to alcohol-related liver disease<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Aug. 6, 2024 (HealthDay News) — Metabolic dysfunction-associated steatotic liver disease (MASLD)-related and metabolic and alcohol-related liver disease (MetALD)-related cirrhosis is responsible for one-third of cirrhosis cases seen in the intensive care unit (ICU), according to a study published online July 22 in\u00a0Alimentary Pharmacology and Therapeutics<\/em>.<\/p>\n Philippe Sultanik, M.D., Ph.D., from Sorbonne Universit\u00c3\u00a9 in Paris, and colleagues assessed the prevalence of MASLD-related cirrhosis in the ICU (January 2019 to September 2021) among 315 patients (39 with MASLD, 160 with alcohol-related liver disease [ALD], and 116 with MetALD cirrhosis).<\/p>\n The researchers found that patients in the MASLD group were significantly older (65 years versus 57 and 59\u00e2\u0080\u0089years, respectively) and had lower Child-Pugh (8 versus 11 and 10, respectively) and Model for End-Stage Liver Disease scores (17 versus 22 and 21, respectively). There were no differences in one-year transplant-free survival between the groups (53 percent versus 54 and 54 percent, respectively). All groups had cardiovascular mortality of less than 5 percent. The MASLD group had a significantly higher one-year probability of developing hepatic encephalopathy (73 percent versus 27 and 21 percent, respectively).<\/p>\n “MASLD or MetALD was responsible for one-third of the causes of cirrhosis in the ICU,” the authors write. “MASLD-related cirrhosis is as severe as ALD-related cirrhosis. Liver transplantation should be rapidly discussed.”<\/p>\n